Analyst’s Disclosure: I/we have a beneficial long position in the shares of GRFS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advic ...

‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the ...

Core Message - Grifols has received a $21 million grant from The Michael J Fox Foundation for Parkinson's Research to identify plasma-based biomarkers for early detection of Parkinson's disease (PD) through the "Chronos-PD" initiative [1][11] - The initiative aims to revolutionize PD management by detecting the disease years before symptoms appear, enabling the development of new diagnostics and disease-modifying therapies [1][4][5] Grifols' Research and Capabilities - Grifols possesses one of the world's largest collections of biospecimens, with over 100 million plasma samples collected over nearly 15 years, representing thousands of disease states [3][5] - The company leverages its proprietary plasma repository, advanced technology platforms, and plasma proteomics expertise to drive innovative research [4][5] - Grifols' subsidiary Alkahest, specializing in AI and multiomics analysis, is leading the Chronos-PD program [12] Parkinson's Disease Context - PD affects nearly 1 million people in the US and over 6 million worldwide, with limited understanding of its drivers despite decades of research [10] - Current PD diagnosis relies on medical history, physical examination, and brain imaging, often detecting the disease too late to significantly slow or reverse its progression [2] Grifols' Broader Impact - Grifols is a global healthcare leader in plasma-derived medicines and transfusion medicine, operating in over 110 countries with more than 23,000 employees [14][16] - The company focuses on treating conditions across various therapeutic areas, including immunology, neurology, and infectious diseases, driven by patient needs and its growing knowledge of chronic and rare conditions [6][7] - Grifols continues to expand its network of donation centers, which is the world's largest with over 390 centers across multiple regions [15]

Q3 2024 Results - 1 - Q3 2024 Results November 7, 2024 Legal Disclaimer Important Information This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, the Spanish Securities Market and Inv ...

On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.This decision follows the company’s November 19 statement rejecting Brookfield’s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share.Canadian fund Brookfield said it had dropped its plan to take over Spain’s Grifols due to a disagreement over the pharmaceutical company’s value, while Grifols said it concurred with the deci ...

Shares of Grifols (GRFS) lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a common ground over the company's value. Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion). Per management, the valuation “significantly undervalues the company’s fundamental prospects and its long-term potential.” ...

Shares of Grifols (GRFS) lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion).Per a regulatory filing submitted to the SEC, Grifols stated that the valuation offered by Brookfield “significantly undervalues the company’s fundamental prospects and its long-term potential.”Brookfield, along with key shareholders of Grifols, had expressed its intent for a potential t ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of GRFS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advic ...

Shares of Grifols (GRFS) rose nearly 7% on Aug 21 following a report issued by Bloomberg, which stated that Canada-based Brookfield Asset Management is in talks with banks to raise funds worth €9.5 billion ($10.6 billion) in debt for its potential acquisition. Through these funds, Brookfield intends to refinance Grifols' existing debt, which includes loans and high-yield bonds. While most of the funding will be in dollars, the participating banks would be requested to commit to providing the funds 'before s ...

Core Viewpoint - GigaGen Inc. has received FDA clearance for its Investigational New Drug application to initiate a Phase 1 trial for GIGA-2339, a recombinant polyclonal drug aimed at treating hepatitis B virus (HBV) infection, marking a significant advancement in the treatment landscape for HBV [1][5]. Group 1: Company Overview - GigaGen Inc. is a biotechnology company focused on developing transformative antibody drugs for immunodeficiencies, infectious diseases, and checkpoint-resistant cancers [1][16]. - GigaGen's platform utilizes next-generation technology to create recombinant polyclonal antibodies, which are potentially more effective than natural immune responses [11][16]. - GigaGen is a subsidiary of Grifols, a global healthcare company known for its leadership in plasma-derived medicines and transfusion medicine [12][16]. Group 2: Product Development - GIGA-2339 is the first recombinant polyclonal therapeutic in development specifically for chronic HBV infection, with trial initiation expected in Q4 2024 [5]. - The drug contains over 1,000 fully human recombinant anti-HBV antibodies, designed to replicate the natural immune response [1][5]. - GIGA-2339 has demonstrated over 2,000 times the potency of plasma-derived HBV drugs and has shown efficacy in neutralizing and clearing HBV's viral DNA in mouse models [5][11]. Group 3: Market Context - HBV currently affects more than 296 million people globally, leading to over 800,000 deaths annually, with no existing cure available [2][5]. - Existing therapies can only halt viral replication and minimally reduce viral protein levels, highlighting the need for more effective treatments like GIGA-2339 [2][5]. Group 4: Clinical Trial Details - The Phase 1 clinical trial will focus on assessing the safety and tolerability of GIGA-2339 in patients with confirmed HBV infection [3][5]. - The trial is a dose escalation study, which is a common approach in early-phase clinical trials to determine the optimal dosing [3]. Group 5: Strategic Importance - The FDA's clearance of the IND application is seen as a significant milestone in Grifols' commitment to developing innovative antibody drugs for infectious diseases [5]. - GigaGen's approach to creating a diverse range of antibodies positions it uniquely in the market, potentially offering a functional cure for chronic HBV [5][11].